Literature DB >> 8266789

Osteogenesis imperfecta: clinical symptoms and update findings in computed tomography and tympano-cochlear scintigraphy.

U H Ross1, R Laszig, H Bornemann, C Ulrich.   

Abstract

Osteogenesis imperfecta (OI) is an autosomal-dominantly inherited connective tissue disorder characterized by abnormal bone fragility combined with blue sclerae. The association of OI with hearing impairment is commonly known as Van der Hoeve-de Kleyn syndrome. Besides typical symptoms we here report on findings by high resolution CT and by high resolving scintigraphy of the labyrinthine capsule in 3 families (9 patients) with OI, which resemble those in otosclerosis (OS): In 4 of 6 cases with OI and mixed hearing loss, severely decreased peri-cochlear bone density was established by CT. In these cases, increased bone metabolism could be revealed by high resolving tympano-cochlear scintigraphy (TCS) in the cochlear region. In 2 patients with mixed hearing loss and 3 cases without hearing impairment or with slight conductive hearing loss, bone alteration was not detectable by CT and TCS. These results raise the question whether OI and OS lead to similar labyrinthine bone alterations, based on different aetiologies or whether these diseases may co-exist, OS being part of OI.

Entities:  

Mesh:

Year:  1993        PMID: 8266789     DOI: 10.3109/00016489309135874

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Experimental topographic study of high-resolution tympanocochlear scintigraphy using the human temporal bone model.

Authors:  U H Ross; M J Reinhardt; P Reuland
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

2.  Osteogenesis imperfecta of the temporal bone: CT and MR imaging in Van der Hoeve-de Kleyn syndrome.

Authors:  Hatem Alkadhi; Diana Rissmann; Spyros S Kollias
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.